Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1

Prevention strategies for COVID-19 transmission are at the forefront of healthcare paradigms worldwide, the main emphasis of which is vaccination. We present an interesting case of a 37-year-old man who, 3 weeks following his first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Shreena Umit, Khurram, Ruhaid, Lakhani, Anjali, Quirk, Bernadine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070856/
https://www.ncbi.nlm.nih.gov/pubmed/33888484
http://dx.doi.org/10.1136/bcr-2021-242956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070856/
https://www.ncbi.nlm.nih.gov/pubmed/33888484
http://dx.doi.org/10.1136/bcr-2021-242956

Ejemplares similares